Markedly different rates of incident insulin treatment based on universal gestational diabetes mellitus screening in a diverse HMO population

Am J Obstet Gynecol. 2013 Nov;209(5):440.e1-9. doi: 10.1016/j.ajog.2013.06.044. Epub 2013 Jun 28.

Abstract

Objective: We sought to evaluate population gestational diabetes mellitus (GDM) screening results and risk for incident insulin treatment.

Study design: Among 64,687 pregnant women universally screened for GDM from 1995 through 2010 in 2 regions of a large US health plan, we stratified women requiring insulin treatment during their pregnancy by GDM screening results (50-g glucose challenge test [GCT]), followed by a 3-hour, 100-g oral glucose tolerance test if GCT was positive. Women with GCT >200 mg/dL were evaluated separately.

Results: Overall, 2% of all pregnant women required insulin treatment, ranging from 0.1% (normal GCT) to 49.9% (GCT >200 mg/dL; P for trend < .0001). Women with GCT >200 mg/dL had a much higher rate of insulin treatment than women with GDM (odds ratio, 3.7; 95% confidence interval, 3.1-4.4). Risk factors for higher insulin treatment rates with GDM or GCT >200 mg/dL included obesity, race/ethnicity, and diagnosed ≤16 weeks' gestation.

Conclusion: Our results indicate women with GCT >200 mg/dL could be reasonably treated as GDM without requiring additional oral glucose tolerance test for diagnosis.

Keywords: diagnosis; gestational diabetes; insulin; screening.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Cohort Studies
  • Diabetes, Gestational / diagnosis
  • Diabetes, Gestational / drug therapy*
  • Diabetes, Gestational / ethnology
  • Female
  • Glucose Tolerance Test
  • Guideline Adherence / statistics & numerical data*
  • Health Maintenance Organizations
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / therapeutic use*
  • Mass Screening
  • Obesity / complications
  • Practice Guidelines as Topic
  • Pregnancy
  • Retrospective Studies
  • Young Adult

Substances

  • Hypoglycemic Agents
  • Insulin